(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 39.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Fennec Pharmaceuticals's revenue in 2026 is $50,999,000.On average, 8 Wall Street analysts forecast FENC's revenue for 2026 to be $2,393,277,156, with the lowest FENC revenue forecast at $2,120,834,630, and the highest FENC revenue forecast at $2,843,295,380. On average, 8 Wall Street analysts forecast FENC's revenue for 2027 to be $3,482,387,258, with the lowest FENC revenue forecast at $2,781,255,044, and the highest FENC revenue forecast at $3,800,578,452.
In 2028, FENC is forecast to generate $4,890,626,454 in revenue, with the lowest revenue forecast at $3,550,471,836 and the highest revenue forecast at $5,721,883,582.